Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer

BACKGROUND: Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide have been shown to prolong survival in patients with advanced prostate cancer. However, there is limited evidence on the anticancer effect of a reduced dose of ARPIs. This study compared the prognosis in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamada, Shigetomo, Shiota, Masaki, Blas, Leandro, Matsumoto, Takashi, Kashiwagi, Eiji, Takeuchi, Ario, Inokuchi, Junichi, Shiga, Ken-ichiro, Yokomizo, Akira, Eto, Masatoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042776/
https://www.ncbi.nlm.nih.gov/pubmed/35510101
http://dx.doi.org/10.1016/j.prnil.2021.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9042776/
https://www.ncbi.nlm.nih.gov/pubmed/35510101
http://dx.doi.org/10.1016/j.prnil.2021.10.001

Ejemplares similares